Voyager TherapeuticsFRA:VT6 +3.09%54 Net Current Asset Value is €1.45 as of Mar. 2026, which is 100% below its 10-year median of 3.05. GuruFocus rates FRA:VT6 with a GF Score™ of 54/100 and a GF Value™ of €1.32 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 946 Biotechnology companies, Voyager Therapeutics ranks better than 76.53% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Voyager Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was €1.45.
The historical rank and industry rank for Voyager Therapeutics's Net Current Asset Value or its related term are showing as below:
FRA:VT6'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.13 Med: 3.05 Max: 18.03
Current: 2.24
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Voyager Therapeutics was 18.03. The lowest was 1.13. And the median was 3.05.
FRA:VT6's Price-to-Net-Current-Asset-Value is ranked better than 76.53% of 946
companies
in the Biotechnology industry
Industry Median: 4.955
vs FRA:VT6: 2.24
Voyager Therapeutics (FRA:VT6) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Voyager Therapeutics Net Current Asset Value Related Terms
Voyager Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics Net Current Asset Value Chart
FRA:VT6 vs KROS, CDXS, CAMP: Net Current Asset Value Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €1.45 mean?
Voyager Therapeutics (FRA:VT6) has a Net Current Asset Value of €1.45 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Voyager Therapeutics and its competitors. This is 52% below median its historical median of 3.05. Over the past decade, Voyager Therapeutics' Net Current Asset Value has ranged from 1.13 to 18.03. According to the industry distribution chart, Voyager Therapeutics ranks #222 out of 946 companies in the Biotechnology industry, placing it in the top 23.5%.
Is Voyager Therapeutics' Net Current Asset Value too high?
Voyager Therapeutics' current Net Current Asset Value of €1.45 is 52% below median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 1.13 to a high of 18.03. Based on the distribution chart, Voyager Therapeutics ranks #222 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Voyager Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Net Current Asset Value compare to KROS and CDXS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #222 out of 946 companies for Net Current Asset Value. This places Voyager Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.96. Historically, Voyager Therapeutics' own Net Current Asset Value has ranged from 1.13 to 18.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Voyager Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current Net Current Asset Value is €1.45, which is 52% below median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.32, compared to a current price of €3.00 — trading 127.4% above its estimated fair value. The current Net Current Asset Value is €1.45, which is 52% below median its 10-year median of 3.05. Voyager Therapeutics' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Net Current Asset Value is €1.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €3.00 is trading 127.4% above its estimated GF Value™ of €1.32.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Net Current Asset Value: €1.45 (52% below median its 10-year median of 3.05)
GF Value™: €1.32 vs. price of €3.00 (127.4% above fair value)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
54GF Score
Get the complete analysis for FRA:VT6
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
